← Specialty Natural Products PCL overview

Specialty Natural Products PCL vs LOréal: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Specialty Natural Products PCL (SNPS.BK)

Q3 2026
▲3▼1

SNPS: weak Q2 margins, but Indonesia demand and new plant drive growth

  • Weak Q2 profit and broker downgrade SNPS's Q2 profit came in weak, with margin squeezed as extract costs rose with oil prices while selling prices stayed flat. Brokers cut the 2026 profit forecast and target price to 5 baht, downgrading the stock to TRADING. This weighs on the share price.

    This is the main negative force on the stock and explains the recent price weakness.

  • Indonesia orders and rainy-season cough demand SNPS sees clear growth in Indonesia, with natural colour orders expected to rise significantly by year-end. The rainy season is boosting partner sales of cough and lung care products that use its extracts. A weaker baht also lifts margins on overseas sales, supporting revenue growth.

    This is a new demand driver that supports future revenue and profit growth.

  • New Bang Phli plant on track for end-2026 SNPS is building a new plant in Bang Phli, due by end-2026, to make medicines and medical devices from herbal active ingredients. It targets 15-30% revenue growth this year and keeps a ~40% gross margin. Analysts expect H2 profit to recover to about 26 million baht per quarter.

    This shows a concrete expansion that could drive future sales and profit recovery.

  • Regulatory push and import-risk warning SNPS backs a Positive Lists health claims system to cut product development time and cost, helping its natural extracts business. Its CEO also warned that Thailand imports over 80% of drugs and 90% of key ingredients, urging faster local production. Both support the long-term case for SNPS.

    These policy and supply-chain themes could benefit SNPS's domestic production and product approvals over time.

August 2026
▲3▼1

SNPS: weak Q2 margins, but Indonesia demand and new plant drive growth

  • Weak Q2 profit and broker downgrade SNPS's Q2 profit came in weak, with margin squeezed as extract costs rose with oil prices while selling prices stayed flat. Brokers cut the 2026 profit forecast and target price to 5 baht, downgrading the stock to TRADING. This weighs on the share price.

    This is the main negative force on the stock and explains the recent price weakness.

  • Indonesia orders and rainy-season cough demand SNPS sees clear growth in Indonesia, with natural colour orders expected to rise significantly by year-end. The rainy season is boosting partner sales of cough and lung care products that use its extracts. A weaker baht also lifts margins on overseas sales, supporting revenue growth.

    This is a new demand driver that supports future revenue and profit growth.

  • New Bang Phli plant on track for end-2026 SNPS is building a new plant in Bang Phli, due by end-2026, to make medicines and medical devices from herbal active ingredients. It targets 15-30% revenue growth this year and keeps a ~40% gross margin. Analysts expect H2 profit to recover to about 26 million baht per quarter.

    This shows a concrete expansion that could drive future sales and profit recovery.

  • Regulatory push and import-risk warning SNPS backs a Positive Lists health claims system to cut product development time and cost, helping its natural extracts business. Its CEO also warned that Thailand imports over 80% of drugs and 90% of key ingredients, urging faster local production. Both support the long-term case for SNPS.

    These policy and supply-chain themes could benefit SNPS's domestic production and product approvals over time.

Latest
▲3▼1

SNPS: weak Q2 margins, but Indonesia demand and new plant drive growth

  • Weak Q2 profit and broker downgrade SNPS's Q2 profit came in weak, with margin squeezed as extract costs rose with oil prices while selling prices stayed flat. Brokers cut the 2026 profit forecast and target price to 5 baht, downgrading the stock to TRADING. This weighs on the share price.

    This is the main negative force on the stock and explains the recent price weakness.

  • Indonesia orders and rainy-season cough demand SNPS sees clear growth in Indonesia, with natural colour orders expected to rise significantly by year-end. The rainy season is boosting partner sales of cough and lung care products that use its extracts. A weaker baht also lifts margins on overseas sales, supporting revenue growth.

    This is a new demand driver that supports future revenue and profit growth.

  • New Bang Phli plant on track for end-2026 SNPS is building a new plant in Bang Phli, due by end-2026, to make medicines and medical devices from herbal active ingredients. It targets 15-30% revenue growth this year and keeps a ~40% gross margin. Analysts expect H2 profit to recover to about 26 million baht per quarter.

    This shows a concrete expansion that could drive future sales and profit recovery.

  • Regulatory push and import-risk warning SNPS backs a Positive Lists health claims system to cut product development time and cost, helping its natural extracts business. Its CEO also warned that Thailand imports over 80% of drugs and 90% of key ingredients, urging faster local production. Both support the long-term case for SNPS.

    These policy and supply-chain themes could benefit SNPS's domestic production and product approvals over time.

LOréal S.A. (OR.PA)

Q3 2026
▲3

L'Oréal gains on beauty shift, deals, and AI marketing

  • Strong H1 results and record margin H1 sales rose 6.5% like-for-like to €23.77bn with a record 21.3% operating margin, and Q2 beat expectations on haircare and mascara demand, showing resilient consumer appetite.

    This explains the fundamental strength that supported the stock during the period.

  • Strategic acquisitions and license wins L'Oréal secured the Gucci beauty license early, acquired Kering's beauty division for $4.7bn, Innovist and Onesto Labs, and is eyeing an Armani stake, expanding its brand portfolio.

    These deals are major strategic moves that could drive future growth and were new in the period.

  • Chinese consumers shift to premium beauty Chinese consumers are moving from luxury fashion to premium beauty, helping L'Oréal overtake LVMH as France's most valuable listed company, a significant market shift.

    This consumer trend directly boosted L'Oréal's relative valuation and market position.

  • AI marketing and bond raise, but risks remain AI now drives ~20% of marketing and a €2bn bond adds flexibility, but luxury missed forecasts, travel retail remains weak, and dealmaking plus the bond raise carry integration and leverage risks.

    This captures both the efficiency gains and the real counterweights that could pressure the stock.

September 2026
▲4

L'Oréal gains from China beauty shift, dealmaking and AI push

  • Chinese consumers shift to premium beauty Chinese shoppers are cutting back on luxury fashion but still buying premium skincare and cosmetics. L'Oréal's luxury beauty division in China grew 10% last quarter, and 37% of high-spending Chinese consumers plan to spend more on beauty next year. This supports demand for OR.PA.

    This is a core demand driver showing why L'Oréal is outperforming luxury peers in a key market.

  • L'Oréal becomes France's most valuable listed company L'Oréal overtook LVMH as France's most valuable listed company, helped by the 'lipstick effect' — when money is tight, people still treat themselves to affordable beauty items. L'Oréal shares are up about 5% this year while LVMH is down 35%, showing a clear investor preference for beauty over high fashion.

    This milestone reflects the market's recognition of L'Oréal's relative strength and the shift in consumer spending.

  • Dealmaking spree: Kering beauty, Onesto Labs, Armani stake L'Oréal bought Kering's beauty division for $4.7 billion, won approval to buy India's Onesto Labs, and is in talks for a minority stake in Giorgio Armani. These moves expand its luxury and consumer brands, deepen its fragrance and cosmetics reach, and add growth in India. They strengthen future earnings power.

    These deals are major capital actions that expand L'Oréal's portfolio and market reach, directly affecting its growth outlook.

  • AI-led marketing and €2bn bond for flexibility L'Oréal says nearly 20% of its marketing spend is now AI-led, improving efficiency and consumer targeting. It also priced a €2 billion bond to fund general corporate needs, giving it cheap, long-term money. Both support profit margins and future investments.

    These show operational efficiency gains and financial strength, which underpin the company's ability to grow and invest.

Latest
▲4

L'Oréal gains from China beauty shift, dealmaking and AI push

  • Chinese consumers shift to premium beauty Chinese shoppers are cutting back on luxury fashion but still buying premium skincare and cosmetics. L'Oréal's luxury beauty division in China grew 10% last quarter, and 37% of high-spending Chinese consumers plan to spend more on beauty next year. This supports demand for OR.PA.

    This is a core demand driver showing why L'Oréal is outperforming luxury peers in a key market.

  • L'Oréal becomes France's most valuable listed company L'Oréal overtook LVMH as France's most valuable listed company, helped by the 'lipstick effect' — when money is tight, people still treat themselves to affordable beauty items. L'Oréal shares are up about 5% this year while LVMH is down 35%, showing a clear investor preference for beauty over high fashion.

    This milestone reflects the market's recognition of L'Oréal's relative strength and the shift in consumer spending.

  • Dealmaking spree: Kering beauty, Onesto Labs, Armani stake L'Oréal bought Kering's beauty division for $4.7 billion, won approval to buy India's Onesto Labs, and is in talks for a minority stake in Giorgio Armani. These moves expand its luxury and consumer brands, deepen its fragrance and cosmetics reach, and add growth in India. They strengthen future earnings power.

    These deals are major capital actions that expand L'Oréal's portfolio and market reach, directly affecting its growth outlook.

  • AI-led marketing and €2bn bond for flexibility L'Oréal says nearly 20% of its marketing spend is now AI-led, improving efficiency and consumer targeting. It also priced a €2 billion bond to fund general corporate needs, giving it cheap, long-term money. Both support profit margins and future investments.

    These show operational efficiency gains and financial strength, which underpin the company's ability to grow and invest.

July 2026
▲4

L'Oréal beats forecasts, buys growth, and adds Gucci beauty

  • H1 results beat expectations with record margin L'Oréal's first-half sales rose 6.5% like-for-like to €23.77bn, with a record 21.3% operating margin. All four divisions grew, led by Professional Products and Dermatological Beauty. Strong profit and broad-based growth support a higher share price.

    This is the core earnings event that directly drives investor confidence and valuation.

  • Q2 sales beat forecasts on haircare and mascara demand Second-quarter like-for-like sales rose 6.3%, beating the 5.7% consensus, with Europe up 6.7% and North America up 5.9%. Luxury missed forecasts but China showed double-digit growth. The beat signals resilient consumer demand despite travel retail weakness.

    It confirms the growth trend and shows demand is holding up in key regions.

  • Gucci beauty license starts early, expanding prestige portfolio Coty will exit its Gucci beauty license a year early, letting L'Oréal begin a 50-year exclusive license from July 2027. L'Oréal covers about 70% of Coty's early redemption costs. This adds a major luxury brand to its prestige lineup.

    It is a new, long-term revenue stream that strengthens L'Oréal's luxury division.

  • Acquires Innovist in India and eyes Armani stake L'Oréal agreed to buy a majority stake in Indian digital-first personal care house Innovist, adding brands like Bare Anatomy. It is also named as a possible buyer of a stake in Giorgio Armani Group. Both moves expand reach in fast-growing markets and prestige.

    These deals show management actively deploying capital for future growth.

▲4

L'Oréal beats forecasts, buys growth, and adds Gucci beauty

  • H1 results beat expectations with record margin L'Oréal's first-half sales rose 6.5% like-for-like to €23.77bn, with a record 21.3% operating margin. All four divisions grew, led by Professional Products and Dermatological Beauty. Strong profit and broad-based growth support a higher share price.

    This is the core earnings event that directly drives investor confidence and valuation.

  • Q2 sales beat forecasts on haircare and mascara demand Second-quarter like-for-like sales rose 6.3%, beating the 5.7% consensus, with Europe up 6.7% and North America up 5.9%. Luxury missed forecasts but China showed double-digit growth. The beat signals resilient consumer demand despite travel retail weakness.

    It confirms the growth trend and shows demand is holding up in key regions.

  • Gucci beauty license starts early, expanding prestige portfolio Coty will exit its Gucci beauty license a year early, letting L'Oréal begin a 50-year exclusive license from July 2027. L'Oréal covers about 70% of Coty's early redemption costs. This adds a major luxury brand to its prestige lineup.

    It is a new, long-term revenue stream that strengthens L'Oréal's luxury division.

  • Acquires Innovist in India and eyes Armani stake L'Oréal agreed to buy a majority stake in Indian digital-first personal care house Innovist, adding brands like Bare Anatomy. It is also named as a possible buyer of a stake in Giorgio Armani Group. Both moves expand reach in fast-growing markets and prestige.

    These deals show management actively deploying capital for future growth.